BLKB vs PTRN

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no Altman Z-Score available to confirm safety from distress. Despite strong operating margins and recent earnings beats, the company is unprofitable overall (negative net margin and ROE), carries an extremely high debt/equity ratio of 9.93, and shows weak liquidity. Valuation multiples like a Price/Book of 24.60 appear stretched against poor profitability, while insider selling and declining revenue further undermine confidence. The stock trades below analyst targets but faces significant structural and financial headwinds.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.